Liquidia Corp Chief Accounting Officer Dana Boyle reported selling 1,581 shares of common stock on October 26, 2026, at $43.19 per share. The shares were sold to cover taxes associated with the settlement of restricted stock units. The transaction was made under a Rule 10b5-1 plan adopted December 15, 2023; Boyle reported 164,028 shares following the transaction.
Liquidia Corp (LQDA) Chief Business Officer Jason Adair sold 688 shares of common stock on October 26, 2026, at $43.19 per share to cover taxes associated with settling restricted stock units (RSUs). The sale was made under a Rule 10b5-1 plan adopted December 15, 2023. He directly held 177,269 shares after the transaction; that figure includes unvested RSUs and shares acquired under Liquidia Corporation's 2020 Employee Stock Purchase Plan.
Liquidia Corporation’s subsidiary, Liquidia Technologies, entered into a settlement with United Therapeutics covering all ongoing litigation between them. Liquidia Technologies will pay UTC $175.0 million net within 30 business days of the October 13, 2026 effective date, plus $145.4 million in two equal $72.7 million installments due on or before January 31, 2027 and April 30, 2027. Related agreements provide for $60.3 million in aggregate payments to parties with interests in the related litigation. A September 30, 2026 court ruling found claims 1 and 14 of a patent valid and infringed; Liquidia agreed not to appeal.
Liquidia will continue marketing YUTREPIA for PAH, while agreeing to seek FDA approval to remove PH-ILD from the product label and cease PH-ILD promotion. The mutual releases become effective only after Liquidia pays UTC, dismissals with prejudice are filed, and FDA approves the label change. A seventh amendment raises the minimum cash covenant under the HCR financing agreement from $15.0 million to $45.0 million. Cash and cash equivalents were $396.1 million as of September 30, 2026; preliminary, unaudited third-quarter YUTREPIA net product sales were $222.7 million.
Liquidia Corp General Counsel Russell Schundler reported selling 13,692 common shares at $28.48 per share on October 12, 2026, to cover taxes associated with the settlement of restricted stock units and performance stock units. The sale was made pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
On October 9, 2026, 3,758 and 6,409 performance stock units converted into matching amounts of common stock on a one-for-one basis. A separate holding entry lists 14,500 common shares held by his spouse; Schundler disclaims beneficial ownership except to the extent of his pecuniary interest.
Liquidia Corp (LQDA) Chief Medical Officer Rajeev Saggar sold 9,218 common shares on October 12, 2026, at $28.48 per share. The sale covered taxes associated with settlements of restricted and performance stock units and was made under a Rule 10b5-1 plan adopted December 15, 2023.
Saggar's October 9, 2026 transactions also included performance stock unit conversions into common stock. As of October 9, 2026, Saggar Legacy Trust held 15,099 shares indirectly; Saggar is the trust's trustee.
Liquidia Corp's Chief Commercial Officer, Scott Moomaw, acquired common stock through Performance Stock Unit conversions of 3,108 and 4,358 shares on October 9, 2026; each PSU converts one-for-one. He sold 8,863 shares on October 12, 2026, at $28.48 per share to cover taxes on RSU and PSU settlements. The sale was made pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
Liquidia Corp (LQDA) Chief Human Resource Officer Sarah Krepp converted 3,178 performance stock units into 3,178 common shares on October 9, 2026, on a one-for-one basis. The transaction row reports 28,609 performance stock units following the conversion. On October 12, she sold 5,245 common shares at $28.48 per share to cover taxes associated with settling RSUs and PSUs. The sale was made under a Rule 10b5-1 plan adopted December 15, 2023.
Liquidia Corp Chief Development Officer Sanjeev Khindri sold 1,101 common shares on October 12, 2026, at $28.48 per share. The transaction was made under a Rule 10b5-1 plan adopted March 9, 2026; the shares covered taxes associated with settlement of restricted stock units initially granted February 10, 2025. Khindri reported 64,846 shares after the sale.
Liquidia Corp (LQDA) CFO and COO Michael Kaseta reported converting 5,828 and 7,049 performance stock units into common stock on October 9, 2026. On October 12, 2026, he sold 18,938 common shares at $28.48 per share under a Rule 10b5-1 plan adopted December 15, 2023. The sale covered taxes associated with settlement of RSUs and PSUs granted on January 11, 2023, January 11, 2024, January 15, 2024, and January 11, 2025.
Liquidia Corp (LQDA) CEO Roger Jeffs sold 32,744 common shares at $28.48 per share on October 12, 2026, to cover taxes associated with settlement of RSUs and PSUs initially granted on January 11, 2023, January 11, 2024, and January 11, 2025. On October 9, 2026, he converted 13,833 and 14,333 performance stock units into common stock on a one-for-one basis. The sale was made under a Rule 10b5-1 plan adopted December 15, 2023.